Company Filing History:
Years Active: 2020
Title: Lars Sejergaard: Innovator in Polypeptide Modification
Introduction
Lars Sejergaard is a notable inventor based in Albertslund, Denmark. He has made significant contributions to the field of biotechnology, particularly in the area of polypeptide modification. His work has implications for pharmaceutical applications, showcasing the intersection of science and innovation.
Latest Patents
Lars Sejergaard holds a patent for a method of controlling a polypeptide modification reaction. This invention specifically addresses the activation of human factor VII (FVII) to produce human factor VII(a) (FVII(a)). The patent also encompasses polypeptides obtainable through this modification reaction and pharmaceutical compositions that include these polypeptides. He has 1 patent to his name, reflecting his innovative approach to biochemistry.
Career Highlights
Lars is currently employed at Novo Nordisk Healthcare AG, a leading global healthcare company focused on diabetes care and other serious chronic conditions. His role at Novo Nordisk allows him to apply his expertise in polypeptide modification to develop new therapeutic solutions.
Collaborations
Lars collaborates with Janus Krarup, a fellow professional in the field. Their partnership exemplifies the collaborative spirit often found in research and development environments, where shared knowledge leads to groundbreaking advancements.
Conclusion
Lars Sejergaard's contributions to the field of biotechnology, particularly through his patent on polypeptide modification, highlight his role as an innovator. His work at Novo Nordisk Healthcare AG continues to influence the development of new therapeutic options.